On July 17, 3SBio fell 5.64% in regular trading, trading at 16.35 HKD/share, with turnover of HKD 357 million.

On the news front, Orient Securities sold 6.131 million shares of 3SBio on July 10 at approximately HKD 17.87 per share, totaling around HKD 110 million, reducing its stake to 6.97%. Earlier, Huatai-PineBridge Fund also reduced its holding by 6.131 million shares at a similar price on July 14. Consecutive institutional disposals have weighed heavily on market sentiment.

The broader Biotechnology sector also saw broad-based weakness, with AKESO down 9.09%, Remegen down 7.35%, SKB Bio down 4.92%, Innovent Bio down 3.66%, and BeiGene down 2.62%, amplifying selling pressure on 3SBio.

3SBio is an investment holding company principally engaged in the development, production, marketing, and sale of biopharmaceutical products, including Tpiao, Epiao, and Yisaipu, with operations also covering CDMO services.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)